• Explore /
  • Poster
  • / Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.

Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.

Abstract Video & Slides Poster

Authors

Thierry Andre

Thierry Andre

Sorbonne University, Saint-Antoine Hospital, AP-HP, Paris, France

Thierry Andre , Dominique Berton , Giuseppe Curigliano , Begona Jimenez-Rodriguez , Susan Ellard , Adriano Gravina , Rowan Miller , Anna Tinker , Andrea Jewell , Joanna Pikiel , Ana Oaknin , Tao Duan , Sybil Zildjian , Eleftherios Zografos , Jennifer Taylor Veneris , Susana N. Banerjee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Monotherapy

Clinical Trial Registration Number

NCT02715284

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2587)

DOI

10.1200/JCO.2022.40.16_suppl.2587

Abstract #

2587

Poster Bd #

242

Abstract Disclosures

Similar Posters

Poster

2020 Gastrointestinal Cancers Symposium

Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.

Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.

First Author: Thierry Andre

First Author: Thierry Andre

First Author: Dominique Berton

First Author: Florence Joly